Baidu
map

Gut:HBV患者血清dlDNA比例的增加与肝病的进展有关

2015-06-27 MedSci MedSci原创

Gut:HBV患者血清dlDNA比例的增加与肝病的进展有关HBV具有两种形式的基因组,松弛环状DNA(rcDNA)和复式线状DNA(dlDNA)。研究表明,与rcDNA相比,dlDNA更常见整合至宿主细胞染色体中,并有致癌的倾向。然而,相对于总的HBV DNA,dlDNA的比例以及其临床意义仍有待研究。基于 rcDNA 和dlDNA之间结构的差异,研究人员开发出一种肽核酸(PNA)介导的实时定量P





HBV具有两种形式的基因组,松弛环状DNA(rcDNA)和复式线状DNA(dlDNA)。研究表明,与rcDNA相比,dlDNA更常见整合至宿主细胞染色体中,并有致癌的倾向。然而,相对于总的HBV DNA,dlDNA的比例以及其临床意义仍有待研究。


基于 rcDNA 和dlDNA之间结构的差异,研究人员开发出一种肽核酸(PNA)介导的实时定量PCR(qPCR)钳夹方法,以检测慢性乙肝B(CHB)患者、肝硬化(LC)患者或LC基础上发展为肝细胞肝癌(HCC)的患者血清中dlDNA和总HBV DNA的比例。同时对影响dlDNA比例的因素进行研究。

结果发现,慢性HBV感染患者的血清中 dlDNA的平均比例约为7%,CHB患者中,dlDNA的比例随着丙氨酸转移酶的异常水平而增加。LC和HCC患者血清中dlDNA的比例分别约为14%和20%。干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。此外,体外研究表明,伴有炎症细胞因子升高的HBV复制可显著改变dlDNA的比例。

总而言之,该研究中,研究人员使用新型PNA介导的qPCR钳夹方法,首次发现了HBV相关性肝病发展过程中患者血清dlDNA的比例逐步增加。dlDNA的比例可受炎性因子的调节,表明验证中HBV dlDNA的比例增高可能与HCC的发生有关。

原始出处:

Zhao XL, Yang JR, Lin SZ, Ma H, Guo F, Yang RF, Zhang HH, Han JC, Wei L, Pan XB.Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected withHBV. Gut. 2015 Jun 4. pii: gutjnl-2014-308989. doi: 10.1136/gutjnl-2014-308989.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2016-03-16 klivis
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-07-29 longjun

    学习了,挺不错的

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-07-11 1dd8dc08m63(暂无匿称)

    干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-29 Rosechen2953

    期待基于此而来的疾病新疗法

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-29 huaxipanxing

    厉害

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-29 medcardio

    中国没有这种原创的创新的研究。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-28 owlhealth

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-28 summer474cn

    o

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1836602, encodeId=882d183660266, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Mar 16 05:06:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33787, encodeId=168e33e8724, content=学习了,挺不错的, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237e1636404, createdName=longjun, createdTime=Wed Jul 29 14:27:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32365, encodeId=474f323652d, content=干扰素-α治疗可使应答者的dlDNA比例轻度增加;核苷酸类似物治疗可使dlDNA的比例不合逻辑的升高。?什么意思,那抗病毒治疗后dlDNA比例升高,意味着什么,肿瘤风险增高?, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=949f1631928, createdName=1dd8dc08m63(暂无匿称), createdTime=Sat Jul 11 15:07:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29925, encodeId=dc1f29925be, content=期待基于此而来的疾病新疗法, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30461627905, createdName=Rosechen2953, createdTime=Mon Jun 29 18:52:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29820, encodeId=73ce298208d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon Jun 29 09:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29803, encodeId=8a0a29803db, content=中国没有这种原创的创新的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 29 00:02:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29770, encodeId=970229e706d, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sun Jun 28 13:46:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29719, encodeId=42c329e1996, content=o, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sun Jun 28 06:48:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29715, encodeId=51b429e159a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Sun Jun 28 01:09:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-28 zm0805

    0

相关资讯

罗氏推出新一代乙肝(HBV)病毒载量试剂盒cobas HBV

瑞士制药巨头罗氏(Roche)近日宣布,在所有承认CE标识的市场商业化推出应用于cobas 6800/8800系统的cobas HBV定量核酸检测试剂盒。该款cobas HBV试剂盒将在所有关键医疗决策点提供针对所有已知乙肝(HBV)基因型(A-H)的高灵敏度和广覆盖面。cobas HBV试剂盒及cobas 6800/8800系统在所有承认CE标志的国家和地区上市,但目前尚未在美国上市。 c

从免疫学角度,论抗HBV治疗新策略

免疫应答的动力学:HBV感染早期是关键  既往针对HBV感染动物模型(黑猩猩、土拨鼠等)的研究数据表明,机体干扰素(IFN)的诱导基因表达不足,导致了对HBV感染先天性免疫应答的效应缺陷,所诱导的早期细胞内免疫应答非常微弱,表现为一种隐性病毒感染,不易被先天性免疫系统所察觉。纵向研究表明,急性HBV感染所引起的相关细胞因子和趋化因子的应答与急性HIV感染相比明显偏弱、延迟,其结果与动物模型研究

Nat Med:揭示乙肝难愈之谜

由伦敦大学学院(UCL)领导的一项新研究揭示,乙型肝炎通过刺激一些过程夺去了机体免疫细胞发挥功能必需的关键营养物质。研究人员将他们的结果发布在5月11日的《自然医学》(Nature Medicine)杂志上。这项研究工作有助于解释一旦乙型肝炎病毒(HBV)在肝脏中建立感染,免疫系统变无法控制这种感染的原因,并为沿着这条路开发出潜在的治愈性疗法提供了一个靶点。此外,研究还为我们提供了一些有关控制免疫

Journal of Hepatology:慢性HBV感染的死亡原因分析

我们可能笼统的知道,当感染了乙肝病毒(HBV)后,容易进展为肝炎、肝硬化、肝细胞癌,并且最终可能死于上述原因,但HBV相关的死亡率具体有多少并不清楚,来自法国的一项研究回答了上述问题。这项研究发表在近期的Journal of Hepatology上。 他们通过一项以人群为基础的队列研究来调查慢乙肝患者较普通人群死亡风险有多大,并且区分所有原因死亡率和HBV相关死亡率的风险因素。 方法 一个专

APASL乙型肝炎指南更新版解读

我国HBV感染者总人口为9300万,其中需要治疗的慢性乙型肝炎患者共计3000万,700万为急需治疗的严重活动性慢性乙型肝炎患者。因此,大量患者处于疾病进展高风险。过去十多年来,有效的抗病毒药物的上市,使得临床医生和慢性乙型肝炎患者共同进入到积极抗击HBV的时代,并在实践中证明了有效的抗HBV治疗可以降低疾病进展至肝硬化、肝细胞肝癌(HCC)的风险。核苷(酸)类似物(NA)和干扰素作为两大类被

Hepatology:替诺福韦酯能降低乙肝孕妈妈后代乙肝传染(PreMIT研究)

乙肝孕妇在中国并不少见,很多孕妇及家属都会担心其宫内胎儿的情况。目前替诺福韦酯(TDF)在临床上对于普通人群应用较广,并且效果得到肯定。其具有抑制乙型肝炎病毒(HBV)复制的作用,同时可以在一定程度能降低体内相关转氨酶水平,起到保护肝脏的作用。但是目前关于替诺福韦酯(TDF)在孕妇中的运用、对于减少乙型肝炎病毒(HBV)垂直传播的有效性和安全性并不明确。

Baidu
map
Baidu
map
Baidu
map